S. Ashwell

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
S Ashwell, S. Ashwell, Susan Ashwell, Susan Plainsboro Ashwell
Publication record
40 papers · 1,351 citations · H-index 16

PAPERS

Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor.
2020124 citationsauthor #19
Crystal structure of IDH1 R132H mutant in complex with FT-2102
20202 citationsauthor #19
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
201937 citationsauthor #29
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
201270 citationsauthor #2
Checkpoint Kinase and Wee1 Inhibitors as Anticancer Therapeutics
20129 citationsauthor #1
Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.
201224 citationsauthor #2
Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.
201012 citationsauthor #2
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents
201036 citationsauthor #5
Discovery of a Novel Class of Triazolones as Checkpoint Kinase Inhibitors-Hit to Lead Exploration.
20102 citationsauthor #2
Strategies towards more effective anticancer therapies: targeting DNA damage response pathways
20102 citationsauthor #1
Checkpointkinaseinhibitors:a reviewofthepatentliterature
20090 citationsauthor #2
Checkpoint kinase inhibitors: a review of the patent literature
200942 citationsauthor #2
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
2008392 citationsauthor #5
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
200832 citationsauthor #1
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.
200852 citationsauthor #1
Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.
200833 citationsauthor #3
DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
2008164 citationsauthor #1
A Mechanistic Overview of B12‐dependent Processes
20073 citationsauthor #3
Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases
20074 citationsauthor #1
Inhibitors of checkpoint kinases: from discovery to the clinic.
200763 citationsauthor #2
Structure activity and structure property relationships of a novel series of potent inhibitors of Checkpoint kinases
20072 citationsauthor #2
The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
200432 citationsauthor #3
Substituted thiophene and their uses
20040 citationsauthor #1
Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.
2004109 citationsauthor #7
Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists.
20049 citationsauthor #2
Corrigendum to “Synthesis, characterization, and evaluation of pro-drugs of VLA-4 antagonists”
20041 citationsauthor #2
Corrigendum to “Synthesis, characterization, and evaluation of pro-drugs of VLA-4 antagonists”: [Bioorg. Med. Chem. Lett. 14 (2004) 1651]
20040 citationsauthor #2
Caspases: recent advances in small molecule inhibitors
200126 citationsauthor #1
The compounds of the VLA-4 mediated adhesion of leukocytes to inhibit
20000 citationsauthor #4
Acyl derivatives for treatment of diseases which are in connection with vla-4
20000 citationsauthor #4
Acyl-derivatives, which processes VLA-4-related disorders
20000 citationsauthor #1
Intramolecular functionalisation by a methylene radical of a 1,2-diol and a vicinal amino alcohol: models for coenzyme B12-dependent diol dehydratase and ethanolamine ammonia lyase
20008 citationsauthor #2
Acyl derivatives of which deal related VLA-4 disorders.
20000 citationsauthor #1
oxicarbamilo compounds which inhibit leukocyte adhesion mediated by VLA-4.
19980 citationsauthor #1
Compounds having a 4-amino-phenylalanine, mediated VLA-4 inhibit adhesion of leukocytes
19980 citationsauthor #1
Carbamyloxy compounds to inhibit leukocyte adhesion mediated by VLA-4
19980 citationsauthor #9
An improved model for B12-dependent diol dehydrase
19904 citationsauthor #2
Mode of action of vitamin B←1←2 : model studies.
19891 citationsauthor #1
Model experiments pertaining to the mechanism of action of vitamin B12-dependent α-methyleneglutarate mutase
198914 citationsauthor #1
A method for quantitating nanogram amounts of soluble protein using the principle of silver binding.
198545 citationsauthor #4

TIMELINE

1985 45 citations

1989 15 citations

1990 4 citations

1998 0 citations

2000 8 citations

2001 26 citations

2004 151 citations

2007 72 citations

2008 673 citations

2009 42 citations

2010 52 citations

2012 103 citations

2019 37 citations

2020 126 citations

S. Ashwell

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT